ASX
Paradigm Biopharmaceuticals
PAR:ASX•Healthcare
Sensitive ASX Announcement
Paradigm Secures US$27M to Advance Phase 3 OA Trial
Published: 01/07/25, 08:31am (AEST)•8 pages